

Local Coverage Determination (LCD): MolDX: Breast Cancer Index™ (BCI) Gene Expression Test (L37822)

Links in PDF documents are not guaranteed to work. To follow a web link, please use the MCD Website.

Contractor Information

CONTRACTOR NAME	CONTRACT TYPE	CONTRACT NUMBER	JURISDICTION	STATE(S)
Noridian Healthcare Solutions, LLC	A and B MAC	01111 - MAC A	J - E	California - Entire State
Noridian Healthcare Solutions, LLC	A and B MAC	01112 - MAC B	J - E	California - Northern
Noridian Healthcare Solutions, LLC	A and B MAC	01182 - MAC B	J - E	California - Southern
Noridian Healthcare Solutions, LLC	A and B MAC	01211 - MAC A	J - E	American Samoa Guam Hawaii Northern Mariana Islands
Noridian Healthcare Solutions, LLC	A and B MAC	01212 - MAC B	J - E	American Samoa Guam Hawaii Northern Mariana Islands
Noridian Healthcare Solutions, LLC	A and B MAC	01311 - MAC A	J - E	Nevada
Noridian Healthcare Solutions, LLC	A and B MAC	01312 - MAC B	J - E	Nevada
Noridian Healthcare Solutions, LLC	A and B MAC	01911 - MAC A	J - E	American Samoa California - Entire State Guam Hawaii Nevada Northern Mariana Islands

LCD Information

Document Information

LCD ID

L37822

Original Effective Date

For services performed on or after 04/16/2019

LCD Title

MoIDX: Breast Cancer Index™ (BCI) Gene Expression Test

Revision Effective Date

N/A

Proposed LCD in Comment Period

N/A

Revision Ending Date

N/A

Source Proposed LCD

DL37822

Retirement Date

N/A

AMA CPT / ADA CDT / AHA NUBC Copyright Statement

CPT codes, descriptions and other data only are copyright 2018 American Medical Association. All Rights Reserved. Applicable FARS/HHSARS apply.

Notice Period Start Date

02/28/2019

Notice Period End Date

04/15/2019

Current Dental Terminology © 2018 American Dental Association. All rights reserved.

Copyright © 2018, the American Hospital Association, Chicago, Illinois. Reproduced with permission. No portion of the AHA copyrighted materials contained within this publication may be copied without the express written consent of the AHA. AHA copyrighted materials including the UB-04 codes and descriptions may not be removed, copied, or utilized within any software, product, service, solution or derivative work without the written consent of the AHA. If an entity wishes to utilize any AHA materials, please contact the AHA at 312-893-6816. Making copies or utilizing the content of the UB-04 Manual, including the codes and/or descriptions, for internal purposes, resale and/or to be used in any product or publication; creating any modified or derivative work of the UB-04 Manual and/or codes and descriptions; and/or making any commercial use of UB-04 Manual or any portion thereof, including the codes and/or descriptions, is only authorized with an express license from the American Hospital Association. To license the electronic data file of UB-04 Data Specifications, contact Tim Carlson at (312) 893-6816 or Laryssa Marshall at (312) 893-6814. You may also contact us at ub04@healthforum.com.

CMS National Coverage Policy

Title XVIII of the Social Security Act (SSA), §1862(a)(1)(A), states that no Medicare payment shall be made for items or services that “are not reasonable and necessary for the diagnosis or treatment of illness or injury or to improve the functioning of a malformed body member.”

Title XVIII of the Social Security Act, §1833(e), prohibits Medicare payment for any claim lacking the necessary documentation to process the claim.

42 Code of Federal Regulations (CFR) §410.32 Diagnostic x-ray tests, diagnostic laboratory tests, and other diagnostic tests: Conditions.

CMS Internet-Only Manuals, Publication 100-04, Medicare Claims Processing Manual, Ch. 16, §50.5 Jurisdiction of Laboratory Claims, §60.12 Independent Laboratory Specimen Drawing, §60.2. Travel Allowance.

CMS Internet Online Manual Pub. 100-04 (Medicare Claims Processing Manual), Chapter 23 (Section 10) "Reporting ICD Diagnosis and Procedure Codes".

CMS On-Line Manual, Publication 100-02, Medicare Benefit Policy Manual, Chapter 15, §§80.0, 80.1.1, 80.2. Clinical Laboratory services.

Coverage Guidance

Coverage Indications, Limitations, and/or Medical Necessity

This Medicare contractor will provide limited coverage for the Breast Cancer Index™ (BCI) gene expression test (Biotheranostics, Inc., San Diego, CA) for the management of postmenopausal women diagnosed with early-stage (TNM stage T1-3, pN0, M0), node-negative, non-relapsed, ER and/or PR-positive, HER2-negative breast cancer, who are being or will be treated with primary adjuvant endocrine therapy. The BCI test is used by physicians to provide a genomic-based estimate of 10y distant recurrence risk when considering addition of chemotherapy, and/or late distant recurrence risk and endocrine responsiveness when considering extension of endocrine therapy, depending upon when in the continuum of care testing is requested.

Summary of Evidence

Adjuvant therapy decisions initially and at 5 years in ER+ HR- node negative breast cancer

In 2017, approximately 253,000 patients were expected to be diagnosed with invasive breast cancer in the United States,¹ of which approximately 90% are diagnosed with early-stage disease. Hormone-receptor positive (HR+) breast cancer is the most common subtype of breast cancer (~80% of cases¹) and has the most favorable prognosis overall.¹ Standard-of-care treatment for HR+ disease includes primary adjuvant anti-estrogen therapy with tamoxifen, an aromatase inhibitor (AI), or a sequence of these. In addition to anti-estrogen therapy, two key treatment decisions are priorities in the management of early stage breast cancer. The first decision is whether the patient is of sufficient risk of recurrence to recommend systemic adjuvant chemotherapy. In addition, while HR+ early-stage breast cancer patients have a favorable prognosis overall, there is an ongoing risk of distant recurrence (DR) beyond year 5 (late recurrence), and 75% of deaths occur more than 5 years post-diagnosis. As such, the second key decision is whether to

recommend extension of endocrine therapy beyond the initial primary adjuvant therapy. For each treatment decision, physicians and patients must weigh whether the potential benefit from the additional treatment regimen is likely to outweigh the risks of serious toxicities and side effects.

Improving Patient Stratification for Addition of Adjuvant Chemotherapy

Adjuvant chemotherapy has been shown to improve outcomes in patients with early stage HR+ breast cancer. In a meta-analysis of 100,000 women across 123 randomized trials,² the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) reported that patients with early-stage breast cancer experience an approximately 30% reduction in DR rate or benefit from adjuvant chemotherapy. Notably, this analysis also showed that proportional risk reduction was not affected by traditional clinical and pathologic factors (e.g., nodal status, tumor size, tumor grade). Patients therefore with a limited underlying risk of DR will have a lower absolute benefit from chemotherapy, compared to patients with a high underlying risk of DR. For each patient, the expected absolute benefit of chemotherapy needs to be weighed against the 2-3% chance of fatal, life-threatening, or life-changing toxicities.³

Standard clinical and pathologic factors (e.g., tumor size, grade, and nodal status) are commonly used for assessment of a patient's risk of DR to make decisions about the addition of chemotherapy to endocrine therapy. However, molecular tests have been shown to improve prognostic accuracy compared to standard clinical and pathologic features and have become increasingly important for patients with early-stage HR+/HER2- breast cancer to identify patients who have a low risk of DR such that chemotherapy would not provide an overall benefit. In determining the cutoff to identify low risk patients, breast cancer prognostic tests commonly use a threshold of a 10% risk of DR at 10 years. Identification of a group of patients with a risk of DR<10% is a well-accepted standard used by many currently available breast prognostic tests and accepted by the American Society of Clinical Oncology (ASCO).^{3, 4, 5}

Additional Genomic Tools to Weigh Risk-Benefit with Extended Endocrine Therapy

In studies of HR+ patients treated with primary adjuvant endocrine therapy, patients who were DR-free after 5 years had an approximately 10% risk of recurrence during years 5-10.⁵⁻⁷ The critical question of whether longer durations of endocrine therapy would provide additional clinical benefit led to a series of randomized trials that compared the benefit of extended endocrine therapy (EET; 10 years total) versus the 5-year standard of care. The results of these trials demonstrated that EET led to a modest clinical benefit, with statistically significant increases in disease-free survival (3-4% absolute benefit; 10-40% relative risk reduction) in most trials.⁸⁻¹⁴ Analyses of the numbers needed to treat (NNT) from these trials demonstrate that approximately 70-100 patients need to be treated to prevent one DR. While only a small percentage of patients benefit from EET, all patients are at risk of experiencing side effects, which include several serious toxicities such as endometrial cancer, pulmonary embolism, ischemic heart disease and even death in some trials for tamoxifen, and higher rates of osteoporosis, bone fractures, thrombotic events with AIs. In addition to serious safety concerns, prolonged endocrine therapy has numerous lower grade side effects and tolerability challenges that can have a substantial impact on quality of life such as arthralgia, joint pain, and musculoskeletal symptoms with AIs, and hot flashes, fatigue, vaginal dryness, and mood swings with tamoxifen.^{9, 13, 15-17} Side effects and tolerability issues commonly lead to treatment nonadherence or discontinuation of endocrine therapy or EET, causing worse patient outcomes.¹⁸

The large randomized trials have demonstrated that EET is associated with a 10-40% relative reduction in risk of DR.^{8-11, 13, 14, 19} The risk of serious toxicities (e.g., spinal fractures, thrombotic events, and endometrial cancers that lead to deaths) have been reported in ~1-2% of patients treated with EET. If the 28% relative risk reduction from NSABP B-42 is applied to a group of patients with a 7% risk of late DR, the absolute benefit of treatment is at most 2%, which is approximately equivalent to the risk of serious treatment-related toxicities. Therefore, a 7% cutoff for assessing risk versus benefit may be applied, such

that if a biomarker identifies patients with a 7% or lower risk of late DR, the likelihood of benefit from EET is unlikely to outweigh the risks of serious toxicities.

Test Description and Intended Use

The Breast Cancer Index (BCI) is a molecular assay that evaluates the differential expression (qRT-PCR) of 11 genes: 7 informational genes that interrogate multiple cell-signaling pathways associated with breast cancer recurrence [proliferative (Molecular Grade Index or MGI) and estrogen signaling (HoxB13/IL17BR or H/I)], and 4 RNA normalization (reference) genes. The test provides both prognostic and predictive results reported as 1) individualized risk of DR as a percentage based on a BCI Score. Specific risk estimates are generated for the risk of overall DR (0-10 years after diagnosis) and late DR (5-10 years after diagnosis) in patients who are recurrence-free at year 5, and 2) the test separately reports a categorical output of H/I High versus Low for likelihood of endocrine response, with a High H/I ratio associated with endocrine responsive disease.

BCI is used for the management of postmenopausal women diagnosed with early-stage (TNM stage T1-3, pN0, M0), node-negative, non-relapsed, ER and/or PR-positive, HER2-negative breast cancer, who are being treated with primary adjuvant endocrine therapy. The test is used by physicians to provide a genomic-based estimate of distant recurrence risk and endocrine responsiveness to identify patients:

- who have sufficiently low risk of distant recurrence over 10 years, wherein the absolute benefit of adjuvant chemotherapy is unlikely to outweigh the risks of serious toxicities; and/or
- who are distant recurrence-free and have a sufficiently low residual risk of late distant recurrence (post- 5 years from diagnosis) wherein the absolute benefit of extension of endocrine therapy is unlikely to outweigh the risks of complications and nonadherence to therapy

BCI is tested once per patient lifetime on FFPE tissue from the primary tumor specimen obtained prior to adjuvant treatment.

Clinical Validation

Evidence supporting the clinical validity of risk assessment for newly-diagnosed patients considering adjuvant chemotherapy

The prognostic ability of BCI for identifying patients at low risk of both early (0-5y) and cumulative overall DR (0-10 years) in the absence of adjuvant chemotherapy was validated in prospective-retrospective studies in randomized trial cohorts that included ER+ and/or PR+, LN- patients who were treated with adjuvant tamoxifen or AI therapy (Tables 1 and 2).

Table 1: Risk of early DR (years 0-5), by BCI risk group in clinical validation studies

Cohort	Patient subset	No. of Pts	BCI			Hazard ratio (96% CI)		P value			
			BCI Low Risk	Intermediate Risk	BCI High Risk	Intermediate vs Low risk groups	High vs Low risk groups				
			% of Pts	Risk of DR between 0-5y (95% CI)	% of Pts	Risk of DR between 0-5y (95% CI)	% of Pts	Risk of DR between 0-5y (95% CI)			
Stockholm RCT*	Node negative	317	64%	2.0% (0.0-4.0%)	20%	4.8% (0.0-9.9%)	16%	12.2% (2.6-21.0%)	2.31 (0.52-10.3)	6.19 (1.75-21.92)	P=0.0063
TransATAC	Node	665	59%	1.3%	25%	5.6%	16%	18.1%	3.13	8.59	P<0.0001

RCT*	negative			(0.5-3.1%)		(2.9-10.5%)		(12.0-27.0%)		(1.03-24.30)	(3.03-24.30)	
Multi-institutional*	Node negative	358	55%	(1.3-6.9%)	22%	(1.6-13.5%)	23%	(14.6-33.3%)	6.55	(2.89-14.88)	(2.89-14.88)	P<0.0001

* Distant recurrence-free survival data were converted to distant recurrence rates to allow for comparison between studies.

** Hazard ratios in the Stockholm randomized study were based on 0-15yr analysis

Pts, patients.

Table 2: Risk of overall DR (years 0-10), by BCI risk group in clinical validation studies

Cohort	Patient subset	No. of Pts	BCI			Hazard ratio (96% CI)		P value			
			BCI Low Risk	Intermediate Risk	BCI High Risk	Intermediate vs Low risk groups	High vs Low risk groups				
			% of Pts	Risk of DR between 0-10y (95% CI)	% of Pts	Risk of DR between 0-5y (95% CI)	% of Pts	Risk of DR between 0-10y (95% CI)			
Stockholm RCT*	Node negative	317	64%	4.8% (1.7-7.8%)	20%	11.7% (3.1-19.5%)	16%	21.1% (8.5-32.0%)	2.23 (0.91-5.45)	4.79 (2.18-10.5)**	P=0.0063
TransATAC RCT*	Node negative	665	59%	4.8% (3.0-7.6%)	25%	18.3% (12.7-25.8%)	16%	29.0% (21.1-39.1%)	2.89 (1.55-5.40)	4.86 (2.58-9.17)	P<0.0001
Multi-institutional*	Node negative	358	55%	6.6% (2.9-10.0%)	22%	23.3% (12.3-33.0%)	23%	35.8% (24.5-45.5%)	3.54 (1.67-7.48)	6.81 (3.47-13.34)	P<0.0001

* Distant recurrence-free survival data were converted to distant recurrence rates to allow for comparison between studies.

** Hazard ratios in the Stockholm randomized study were based on 0-15yr analysis

Pts, patients.

Development of the 11-gene BCI assay was based on a combination of H/I and MGI using patients from the untreated arm of the Stockholm prospective trial as the training set (n=283). Scores and pre-specified risk groups were then validated in a prospective-retrospective study including 317 ER+, LN- patients treated with primary adjuvant tamoxifen from the Stockholm trial.²⁰ The BCI Low Risk group had only a 6% risk of death due to breast cancer over a 20 year follow-up (years 0-20). Multivariate analyses adjusted for clinicopathologic factors (e.g., patient age, tumor size, tumor grade) showed that BCI was the only significant predictor of DR during years 0-10 (hazard ratio, 5.44; 95% CI, 21.3–13.88; P=0.0004). Further independent validations were performed on a well-annotated multi-institutional cohort of 358 ER+, LN- patients²⁰, and in a prospective-retrospective study evaluating 665 ER+, LN- patients from the translational cohort of the prospective, randomized, controlled ATAC trial.^{20,22} In a multivariate analysis, BCI was a significant prognostic factor for risk of DR from years 0-10 (HR, 2.30; 95% CI, 1.62–3.27; P<0.0001) that included the CTS (a prognostic algorithm based on classic clinical and pathologic factors of tumor size/grade, LN status, patient age, and treatment).²² These studies collectively demonstrate the ability of BCI to significantly stratify patients based on risk of DR, and to identify a low risk group (55-64% of patients across studies) with excellent 10 year outcomes (4.8-6.6% DR rate) when treated with a regimen

of 5 years of endocrine therapy only. BCI was also determined to provide independent prognostic information compared to clinical and pathologic features alone.

Evidence supporting the clinical validity of risk assessment for patients who are distant recurrence-free at year 5 considering extended endocrine therapy.

Evaluation of BCI prognostic performance for late DR was performed in ER+ and/or PR+, LN- patients who were treated with no more than 5 years of adjuvant tamoxifen or AI therapy and were DR-free at 5 years (Table 3).

Table 3: Risk of late DR (years 5-10) in patients who were disease free following 5 years of adjuvant endocrine therapy, by BCI risk group in validation studies

Cohort	Patient subset	No. of Pts	BCI			Hazard ratio (95% CI)		P value
			BCI Low Risk % of Pts Risk of DR between 0-10y (95% CI)	Intermediate Risk % of Pts Risk of DR between 0-5y (95% CI)	BCI High Risk % of Pts Risk of DR between 0-10y (95% CI)	Intermediate vs Low risk groups	High vs Low risk groups	
Stockholm RCT*	Node negative	285	65% 2.8% (0.3-5.2%)	20% 7.2% (0.1-13.8%)	15% 10.1% (0.2-19.1%)	2.2 (0.72-6.73)**	4.04 (1.46-11.14)**	P=0.0152
TransATAC RCT*	Node negative	596	61% 3.5% (2.0-6.1%)	25% 13.4% (8.5-20.5%)	14% 13.3% (7.4-23.4%)	2.93 (1.37-6.29)	2.97 (1.23-7.13)	P<0.0001
Multi-institutional*	Node negative	312	58% 2.5% (0-5.0%)	22% 16.9% (6.5-26.2%)	20% 15.0% (5.5-23.6%)	6.9 (2.17-22.02)	7.03 (2.17-22.84)	P<0.0002

* DR-free survival was converted to DR rates to allow for comparison between studies.

** Hazard ratios in the Stockholm randomized study were based on 5-15yr analysis

Pts, patients

Validation studies for prediction of late DR included 285 ER+, LN- patients that were DR-free following treatment with primary adjuvant tamoxifen, 312 patients that were DR-free following treatment with primary adjuvant treatment, and 596 patients that were DR-free following treatment with primary adjuvant treatment.²⁰ These studies collectively demonstrate the ability of BCI to significantly stratify patients based on risk of late DR, and to identify a low risk group (58-65% of patients across studies) with excellent outcomes in the extended timeframe (<3.5% DR rate from years 5-10 in all studies) when treated with a regimen of 5 years of endocrine therapy only, with a risk of DR that is sufficiently low that the likelihood of benefit from 5 additional years of endocrine therapy is outweighed by the probability of complications and treatment nonadherence.

Evidence supporting the clinical validity of prediction of benefit from endocrine therapy

In addition to stratification of patients based on risk of DR, the BCI assay also reports results from the estrogen signaling biomarker component of BCI—the HoxB13/IL17BR gene expression ratio (H/I). The H/I ratio has been shown to be predictive of benefit from endocrine therapies in 3 prospective randomized study cohorts (N=1514; Table 4).^{20, 26, 27} In each of these studies, a statistically significant interaction between H/I and endocrine treatment was demonstrated. Thus, in all three studies, H/I had statistically significant ability to identify patients likely to benefit from endocrine therapy versus those patients not likely to benefit.

Table 4: Summary of predictive treatment benefit by H/I categorization

Study Cohort	Endocrine Treatment	Relative Risk Reduction by Endocrine Treatment	Interaction P Value
Stockholm (n=600)	Adjuvant tamoxifen vs. untreated	H/I-High HR: 0.35 (0.19-0.65); p=0.0005 H/I-Low HR: 0.67 (0.36-1.24), p=0.2	0.003
TransATAC (n=665)	Adjuvant anastrozole vs. tamoxifen	H/I-High HR: 0.51 (0.27-0.97); p=0.04 H/I-Low HR: 1.33 (0.65-2.71), p=0.4	0.004
MA.17 (n=249)	Extended letrozole vs. placebo	H/I-High OR: 0.33 (0.15-0.73); p=0.006 H/I-Low OR: 0.58 (0.25-1.36), p=0.21	0.03

H/I was validated in the extended (> 5 years) treatment setting in a cohort of patients from the MA.17 trial.²⁷ H/I predicted which patients benefited from treatment with an AI between years 5-10 post-diagnosis. The reduction in risk of recurrence with extended letrozole (an AI) was 16.5% for patients with High H/I (p=0.007), while patients with a Low H/I did not statistically benefit from the extended AI therapy (p=0.35).

Analysis of Evidence (Rationale for Determination)

Level of Evidence

Quality of Evidence – Moderate
Strength – High
Weight - Moderate

The BCI test is covered for postmenopausal women with invasive breast cancer when the following criteria are met:

- Pathology reveals invasive carcinoma of the breast that is ER+ and/or PR+ and HER2-; and
- Patient has early-stage disease (T1-3, pN0, M0); and
- Patient is lymph node negative
- Patient has no evidence of distant breast cancer metastasis (i.e., non-relapsed); and
- Test results will be used in determining treatment management of the patient for chemotherapy and/or extension of endocrine therapy.

Coding Information

Bill Type Codes:

Contractors may specify Bill Types to help providers identify those Bill Types typically used to report this service. Absence of a Bill Type does not guarantee that the policy does not apply to that Bill Type. Complete absence of all Bill Types indicates that coverage is not influenced by Bill Type and the policy should be assumed to apply equally to all claims.

N/A

Revenue Codes:

Contractors may specify Revenue Codes to help providers identify those Revenue Codes typically used to report this service. In most instances Revenue Codes are purely advisory. Unless specified in the policy, services reported under other Revenue Codes are equally subject to this coverage determination. Complete absence of all Revenue Codes indicates that coverage is not influenced by Revenue Code and the policy should be assumed to apply equally to all Revenue Codes.

N/A

CPT/HCPCS Codes**Group 1 Paragraph:**

N/A

Group 1 Codes:

CODE	DESCRIPTION
81518	ONCOLOGY (BREAST), MRNA, GENE EXPRESSION PROFILING BY REAL-TIME RT-PCR OF 11 GENES (7 CONTENT AND 4 HOUSEKEEPING), UTILIZING FORMALIN-FIXED PARAFFIN-EMBEDDED TISSUE, ALGORITHMS REPORTED AS PERCENTAGE RISK FOR METASTATIC RECURRENCE AND LIKELIHOOD OF BENEFIT FROM EXTENDED ENDOCRINE THERAPY

ICD-10 Codes that Support Medical Necessity**Group 1 Paragraph:**

N/A

Group 1 Codes:

ICD-10 CODE	DESCRIPTION
C50.011	Malignant neoplasm of nipple and areola, right female breast
C50.012	Malignant neoplasm of nipple and areola, left female breast
C50.111	Malignant neoplasm of central portion of right female breast
C50.112	Malignant neoplasm of central portion of left female breast
C50.211	Malignant neoplasm of upper-inner quadrant of right female breast

ICD-10 CODE	DESCRIPTION
C50.212	Malignant neoplasm of upper-inner quadrant of left female breast
C50.311	Malignant neoplasm of lower-inner quadrant of right female breast
C50.312	Malignant neoplasm of lower-inner quadrant of left female breast
C50.411	Malignant neoplasm of upper-outer quadrant of right female breast
C50.412	Malignant neoplasm of upper-outer quadrant of left female breast
C50.511	Malignant neoplasm of lower-outer quadrant of right female breast
C50.512	Malignant neoplasm of lower-outer quadrant of left female breast
C50.611	Malignant neoplasm of axillary tail of right female breast
C50.612	Malignant neoplasm of axillary tail of left female breast
C50.811	Malignant neoplasm of overlapping sites of right female breast
C50.812	Malignant neoplasm of overlapping sites of left female breast
C50.911	Malignant neoplasm of unspecified site of right female breast
C50.912	Malignant neoplasm of unspecified site of left female breast
Z17.0	Estrogen receptor positive status [ER+]

ICD-10 Codes that DO NOT Support Medical Necessity

N/A

Additional ICD-10 Information

N/A

General Information

Associated Information

N/A

Sources of Information

N/A

Bibliography

1. Pritchard KI. Extended adjuvant therapy: the role of subset analyses. *Lancet Oncol.* 2017; 18(11): 1431-3.
2. Peto R, Davies C, Godwin J, Gray R, Pan HC, Clarke M, et al. Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. *Lancet.* 2012; 379(9814): 432-44.
3. Harris LN, Ismaila N, McShane LM, Andre F, Collyar DE, Gonzalez-Angulo AM, et al. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline. *J Clin Oncol.* 2016; 34(10): 1134-50.

4. Local Coverage Determination (LCD): MoIDX: EndoPredict Breast Cancer Gene Expression Test (L37264). [cited October 14, 2017].
5. Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, et al. Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1-98 randomised clinical trial at 8.1 years median follow-up. *Lancet Oncol.* 2011; 12(12): 1101-8.
6. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. *Lancet Oncol.* 2010; 11(12): 1135-41.
7. Pan H, Gray GR, Davies C, Peto R, Bergh JCS, Pritchard KI, et al. Predictors of recurrence during years 5-14 in 46,138 women with ER+ breast cancer allocated 5 years only of endocrine therapy (ET). *J Clin Oncol* 2016 (suppl; abstr 505); 34.
8. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. *N Engl J Med.* 2003; 349(19): 1793-802.
9. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. *Journal of the National Cancer Institute.* 2005; 97(17): 1262-71.
10. Mamounas EP, Jeong JH, Wickerham DL, Smith RE, Ganz PA, Land SR, et al. Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. *J Clin Oncol.* 2008; 26(12): 1965-71.
11. Davies C, Pan H, Godwin J, Gray R, Arriagada R, Raina V, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. *Lancet.* 2013; 381(9869): 805-16.
12. Gray GR, Rea D, Handley K, Bowden SJ, Perry P, Earl HM, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. *J Clin Oncol.* 2013; 31: (suppl; abstr 5).
13. Goss PE, Ingle JN, Pritchard KI, Robert NJ, Muss H, Gralow J, et al. Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. *NEJM.* 2016; 375(3): 209-19.
14. Wimmer K, Strobl S, Bolliger M, Devyatko Y, Korkmaz B, Exner R, et al. Optimal duration of adjuvant endocrine therapy: how to apply the newest data. *Ther Adv Med Oncol.* 2017; 9(11): 679-92.
15. Breastcancer.org. Hormonal Therapy Side Effects Comparison Chart. [cited October 15, 2017]; Available from: http://www.breastcancer.org/treatment/hormonal/comp_chart
16. Dent SF, Gaspo R, Kissner M, Pritchard KI. Aromatase inhibitor therapy: toxicities and management strategies in the treatment of postmenopausal women with hormone-sensitive early breast cancer. *Breast Cancer Res Treat.* 2011; 126(2): 295-310.
17. Crew KD, Greenlee H, Capodice J, Raptis G, Brafman L, Fuentes D, et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. *J Clin Oncol.* 2007; 25(25): 3877-83.
18. Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. *Breast Cancer Res Treat.* 2011; 126(2): 529-37.
19. Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM, Swinkels ACP, Smorenburg CH, van der Sangen MJC, et al. Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. *Lancet Oncol.* 2017; 18(11): 1502-11.
20. Zhang Y, Schnabel CA, Schroeder BE, Jerevall PL, Jankowitz RC, Fornander T, et al. Breast cancer index identifies early-stage estrogen receptor-positive breast cancer patients at risk for early- and late-distant recurrence. *Clin Cancer Res.* 2013; 19(15): 4196-205.
21. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. *J Clin Oncol.* 2005; 23(29): 7332-41.
22. Sgroi DC, Sestak I, Cuzick J, Zhang Y, Schnabel CA, Schroeder B, et al. Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index

- (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. *Lancet Oncol.* 2013; 14(11): 1067-76.
23. Sestak I, Buus R, Cuzick J, Dubsy P, Kronenwett R, Denkert C, et al. Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial. *JAMA Oncol.* 2018.
24. Bianchini G, Pusztai L, Karn T, Iwamoto T, Rody A, Kelly C, et al. Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancers. *Breast Cancer Res.* 2013; 15(5): R86.
25. Schroeder B, Zhang Y, Stal O, Fornander T, Brufsky A, Sgroi DC, et al. Risk stratification with Breast Cancer Index for late distant recurrence in patients with clinically low-risk (T1N0) estrogen receptor-positive breast cancer. *NPJ Breast Cancer.* 2017; 3: 28.
26. Sgroi DC, Sestak I, Zhang Y, Erlander ME, Schnabel CA, Goss PE, et al. Evaluation of prognostic and predictive performance of breast cancer index and its components in hormonal receptor-positive breast cancer patients: a TransATAC study. *Cancer Res.* 2012; 72 (Suppl.): Abstract nr P2-10-5.
27. Sgroi DC, Carney E, Zarrella E, Steffel L, Binns SN, Finkelstein DM, et al. Prediction of late disease recurrence and extended adjuvant letrozole benefit by the HOXB13/IL17BR biomarker. *Journal of the National Cancer Institute.* 2013; 105(14): 1036-42.
28. Sanft T, Berkowitz, A., Schroeder, B., Hatzis, C., Schnabel, C.A., Aktas, B., Brufsky, A., Pusztai, L., van Londen, G.J. A multi-institutional, prospective study of incorporating the genomic platform Breast Cancer Index as a tool for decision-making regarding extension of adjuvant endocrine therapy. Poster P2-09-15. San Antonio Breast Cancer Symposium (SABCS). San Antonio, TX; 2016.
29. Sanft T, Aktas B, Schroeder B, Bossuyt V, DiGiovanna M, Abu-Khalaf MM, et al. Prospective assessment of the decision-making impact of the Breast Cancer Index in recommending extended adjuvant endocrine therapy for patients with early-stage ER-positive breast cancer. *Breast Cancer Res Treat.* 2015; 154(3): 533-41.
-

Revision History Information

N/A

Associated Documents

Attachments

N/A

Related Local Coverage Documents

Article(s)

A56356 - Response to Comments: MolDX: Breast Cancer Index™ (BCI) Gene Expression Test

LCD(s)

DL37822 - MolDX: Breast Cancer Index™ (BCI) Gene Expression Test

Related National Coverage Documents

N/A

Public Version(s)

Updated on 02/22/2019 with effective dates 04/16/2019 - N/A

Keywords

- 81518
- MoIDX
- Breast
- BCI
- Biotheranostics
- HER2
- Postmenopausal
- neoplasm